Imaging from inside the artery, balloons that leave nothing behind, and tools for arteries once thought untreatable.
If you've been told you need a stent, you may picture a procedure that hasn't changed in years. In fact, coronary angioplasty has advanced considerably over the past decade — becoming more precise, safer, and longer-lasting than ever before.
The stent remains central to treatment, but how a blockage is assessed, prepared, and treated has transformed. Here are the four most important advances — explained in plain language for patients and referring GPs.
IVUS and OCT probes reveal what an angiogram cannot — wall thickness, calcium, and stent expansion.
Treat selected blockages with medication and no permanent metal implant left behind.
Lithotripsy and atherectomy crack or sand down hardened plaque so stents can open fully.
Thinner-strut stents heal faster, and many patients now need fewer months of dual blood-thinning tablets.

OCT: the artery wall in fine detail, each stent strut a bright dot against the wall.

IVUS: plaque thickens one side; calcium is a bright arc with a dark shadow behind it.
Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are miniature imaging probes — about the width of a few hairs — passed into the artery on a thin wire. They show the vessel from the inside, in cross-section, rather than relying only on the dye-based X-ray outline (the angiogram).
An angiogram shows the shape of the channel, but not the thickness of the artery wall, how much calcium is present, or whether a stent has opened fully. Imaging from inside answers all three — helping choose the right stent size, land it in healthy segments, and confirm it is fully expanded and pressed against the wall.
Several large trials now support imaging guidance for complex blockages, and the results are compelling:
1,639 patients. Imaging guidance cut the combined risk of cardiac death, heart attack, or repeat procedure from 12.3% to 7.7% at a median of 2.1 years — and the benefit persisted with longer follow-up.
1,201 patients with bifurcation lesions. OCT guidance reduced major adverse cardiac events at two years: 10.1% vs 14.1% with angiography alone.
2,487 patients. OCT guidance produced larger, better-expanded stents and fewer stent thromboses.
On this evidence, the 2024 ESC guideline gives intracoronary imaging a Class I recommendation for guiding stenting in anatomically complex lesions — particularly left main, true bifurcation, and long lesions. For patients, imaging guidance means fewer repeat procedures and fewer stent-related problems in the years that follow.

A drug-coated balloon is an angioplasty balloon whose surface carries a medication — usually paclitaxel or sirolimus. During a brief inflation of 30–60 seconds, the drug is pressed into the artery wall. The balloon opens the narrowing and leaves the drug behind to discourage re-narrowing, but no metal stays in the artery.
Avoiding a permanent implant is attractive in certain situations: inside a stent that has re-narrowed, in very small arteries where a stent would leave little room, and in people who cannot take long courses of blood-thinning tablets.

Over years, some plaque hardens into calcium that can be as stiff as bone and may form a complete ring inside the artery. Calcium-modification tools prepare these arteries before a stent goes in — because calcium stops a stent from opening fully, and an under-expanded stent is the one most likely to fail.
A balloon emits sonic pressure waves to crack calcium from within — similar in principle to shockwave treatment for kidney stones. In Disrupt CAD III, 92% of patients were free of major cardiac events at 30 days with good stent expansion.
A tiny, fast-spinning, diamond-coated tip sands down hardened plaque. These are long-established, guideline-supported tools. Note: the ECLIPSE trial (Lancet, 2025) found routine orbital atherectomy did not improve one-year outcomes over careful balloon preparation in lesions suitable for either approach.
These techniques have made some heavily calcified arteries treatable by keyhole angioplasty when, in the past, bypass surgery may have been the only realistic option. Which tool is used depends on the pattern and depth of calcium — exactly what intracoronary imaging reveals.
Today's drug-eluting stents have struts roughly half the thickness of earlier generations, with improved coatings and drugs. Thinner struts heal over faster and are less likely to trigger clots or re-narrowing.
Partly because of this, there has been a clear shift towards shorter courses of two blood-thinning tablets (usually aspirin plus a second agent) in suitable patients. Trials show that shortening the combination to 1–6 months, then continuing a single tablet, reduces bleeding without raising the risk of heart attack or stent clots.
The 2024 ESC guideline reflects this — defaulting to six months after a stent for stable disease, with shorter courses for people at high bleeding risk.
The right duration is individualised. Never stop blood-thinning tablets without speaking to your cardiologist first — even if a relative with a stent took them for a different length of time.

For stable coronary artery disease, medication and risk-factor control remain the foundation of treatment. The landmark ISCHEMIA trial (Maron et al., NEJM, 2020) showed that in stable patients, an early procedure-based strategy did not reduce death or heart attack overall compared with good medical therapy — although it relieved angina more effectively in people with frequent symptoms.
The advances described in this article improve how a procedure is done — more precise, safer, and longer-lasting. They do not change who needs one.
Consistently managed blood pressure reduces strain on coronary arteries and lowers event risk.
Lipid-lowering and glucose control slow plaque progression with or without a stent.
Smoking cessation is one of the most powerful interventions available to any cardiac patient.
Regular physical activity and prescribed medicines consistently remain essential alongside any procedure.
Consider referral to a centre experienced in imaging-guided and complex angioplasty for patients with any of the following. The 2024 ESC guideline gives a Class I recommendation for intracoronary imaging to guide stenting in left main and anatomically complex lesions.
Identified on CT or prior angiography — calcium-modification tools may be required.
Anatomically complex lesions where imaging guidance is now a Class I recommendation.
A completely blocked artery with ongoing symptoms — specialist techniques required.
In-stent restenosis or stent thrombosis — drug-coated balloons and imaging guidance are key.
Where the choice between stenting and bypass surgery is unclear and requires careful assessment.
Being informed helps you get the best outcome. Before your angioplasty, consider asking your cardiologist these five key questions:
Ask whether IVUS or OCT will guide your stent placement.
And if so, how will it be prepared before the stent goes in?
Or could a drug-coated balloon be appropriate for my blockage?
And what is the reason for that specific duration in my case?
To get the best possible long-term result from my procedure.
© 2026 Dr Primero Ng. All rights reserved.
Consultant Interventional Cardiologist, Perth, Western Australia.
Information on this website is general in nature and does not replace individual medical advice.
Beyond the Stent: How Modern Angioplasty Has Changed